VAXART INC by Vaxart, Inc. Analyst Price Targets - Benzinga

VAXART INC by Vaxart, Inc.

VXRTOTCQX

Trade with Public

Trade with Public

$0.4978

0.1855.55%

In chiusura: Jul 17, 5:00 PM EST

Panoramica Notizie Previsioni utili EventiObiettivi di prezzoDati finanziari Sentiment Azionariato Confronta

VAXART INC by Vaxart, Inc. Analyst Price Targets

Wall Street analyst price targets and consensus rating for VAXART INC by Vaxart, Inc. (VXRT).

Price Target Range — 4 Quarters

Analyst Consensus — 3 Analysts

3Buy

Consensus RatingOverweight# Analysts3Avg. Consensus PT$3Upside to Avg. PT+569.0%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Mar 27, 2025	B. Riley Securities	Mayank Mamtani	PT Cut	Buy	$3→$2
Aug 15, 2024	Oppenheimer	Cheng Li	Initiate	Outperform	$4
Jan 31, 2024	B. Riley Securities	Mayank Mamtani	Upgrade	Neutral→Buy	$2
Sep 7, 2023	Cantor Fitzgerald	Charles Duncan	Maintained	Overweight	$4

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
B. Riley Securities Maintains Buy on Vaxart, Lowers Price Target to $2

B. Riley Securities analyst Mayank Mamtani maintains Vaxart (NASDAQ:VXRT) with a Buy and lowers the price target from $2.5 to $2.

Benzinga Newsdesk

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside

Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a bullish outlook on its oral vaccines for COVID-19 and norovirus.

Vandana Singh

PRO
Oppenheimer Initiates Coverage On Vaxart with Outperform Rating, Announces Price Target of $4

Oppenheimer initiates coverage on Vaxart (NASDAQ:VXRT) with a Outperform rating and announces Price Target of $4.

Benzinga Newsdesk

PRO
B. Riley Securities Upgrades Vaxart to Buy, Announces $2 Price Target

B. Riley Securities analyst Mayank Mamtani upgrades Vaxart (NASDAQ:VXRT) from Neutral to Buy and announces $2 price target.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Reiterates Overweight on Vaxart, Maintains $4 Price Target

Cantor Fitzgerald analyst Charles Duncan reiterates Vaxart (NASDAQ:VXRT) with a Overweight and maintains $4 price target.

Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Vaxart, Lowers Price Target to $4

Cantor Fitzgerald analyst Charles Duncan maintains Vaxart (NASDAQ:VXRT) with a Overweight and lowers the price target from $6 to $4.

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved